abstract |
The invention relates to the use of the mineralocorticoid receptor antagonist finerenone combined with valsartan, an angiotensin AII-antagonist, for treating and/or preventing cardiovascular diseases, renal diseases, lung disorders, and for treating and/or prophylaxis of fibrotic diseases. |